story of the week
Brentuximab Vedotin as Consolidation Therapy After Autologous Stem-Cell Transplantation in Patients With Hodgkin's Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brentuximab Vedotin as Consolidation Therapy After Autologous Stem-Cell Transplantation in Patients With Hodgkin's Lymphoma at Risk of Relapse or Progression (AETHERA): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2015 Mar 18;[EPub Ahead of Print], CH Moskowitz, A Nademanee, T Masszi, E Agura, J Holowiecki, MH Abidi, AI Chen, P Stiff, AM Gianni, A Carella, D Osmanov, V Bachanova, J Sweetenham, A Sureda, D Huebner, EL Sievers, A Chi, EK Larsen, NN Hunder, J WalewskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.